. 2022 May 19;26:145. doi: 10.1186/s13054-022-04020-1

Table 2.

Unadjusted and adjusted risk difference between recombinant thrombomodulin use and outcomes among predicted target patients

Predicted target patients	In-hospital mortality	28-day mortality
Test set of the derivation cohort (n = 118)	− 22.0% (− 40.6 to − 3.4%)	− 27.4% (− 41.8 to − 12.9%)	− 20.0% (− 38.2 to − 1.8%)	− 23.6% (− 39.8 to − 7.4%)
Validation cohort (n = 142)	− 15.1% (− 31.1 to 1.0%)	− 31.3% (− 53.5 to − 9.1%)	− 8.4% (− 24.7 to 8.0%)	− 21.1% (− 43.4 to 1.1%)

Predicted target patients

In-hospital mortality

28-day mortality

Unadjusted risk Difference (95% CI)

Adjusted risk difference (95% CI)

Unadjusted risk Difference (95% CI)

Adjusted risk difference (95% CI)

Test set of the derivation cohort (n = 118)

− 22.0%

(− 40.6 to − 3.4%)

− 27.4%

(− 41.8 to − 12.9%)

− 20.0%

(− 38.2 to − 1.8%)

− 23.6%

(− 39.8 to − 7.4%)

Validation cohort (n = 142)

− 15.1%

(− 31.1 to 1.0%)

− 31.3%

(− 53.5 to − 9.1%)

− 8.4%

(− 24.7 to 8.0%)

− 21.1%

(− 43.4 to 1.1%)

In the test set of derivation cohort, the adjusted variables were age, sex, comorbidities, and Sequential Organ Failure Assessment (SOFA) scores

In the validation cohort, the adjusted variables were age, sex, comorbidities, SOFA scores, and in-hospital management, including renal replacement therapy, and treatment with steroids, intravenous immunoglobulin, antithrombin, and vasopressors